Rodden Lori A 4
4 · HARTFORD INSURANCE GROUP, INC. · Filed Feb 13, 2026
Research Summary
AI-generated summary of this filing
HARTFORD (HIG) EVP Lori Rodden Exercises Options, Sells 5,681 Shares
What Happened
Lori A. Rodden, Executive Vice President of Hartford Insurance Group (HIG), exercised 5,681 stock options at an exercise price of $51.87 per share (cost $294,673) and concurrently sold the 5,681 shares in the open market for a weighted-average price of $141.83 per share, generating gross proceeds of approximately $805,723 on Feb 11, 2026. The filing shows the option-to-share conversion and the same-day sale of all shares acquired in this exercise.
Key Details
- Transaction date: February 11, 2026.
- Exercise: 5,681 shares at $51.87 each (total exercise cost $294,673) — reported as code M (exercise/conversion).
- Sale: 5,681 shares sold at a weighted-average price of $141.83 ($141.81–$141.87 range reported) for approximately $805,723 — reported as code S (sale). Footnote F1 explains the weighted-average sale price and range.
- The derivative "Disposed" entry at $0 reflects the option conversion upon exercise (no cash sale of the option itself).
- Shares acquired by exercise were immediately sold (no net shares retained from this tranche).
- Shares owned after the transaction are not specified in the provided summary.
- Filing: Reported on Feb 13, 2026 for a Feb 11 transaction — appears to be filed within the Form 4 timely window.
Context
- This was an exercise of vested options followed by an immediate open-market sale (commonly called a cashless or same-day sale). Such transactions often reflect exercising for liquidity or to cover exercise/tax costs rather than a directional bet on the stock.
- Transaction codes: M = option exercise/conversion, S = sale. Footnotes F2–F6 in the filing describe vesting/exercisability schedules for the related option grants.
Insider Transaction Report
Form 4
Rodden Lori A
Executive Vice President
Transactions
- Exercise/Conversion
Common Stock
2026-02-11$51.87/sh+5,681$294,673→ 24,080.962 total - Sale
Common Stock
[F1]2026-02-11$141.83/sh−5,681$805,723→ 18,399.962 total - Exercise/Conversion
Stock Option
[F2]2026-02-11−5,681→ 0 totalExercise: $51.87Exp: 2031-02-23→ Common Stock (5,681 underlying)
Holdings
- 30,193
Stock Option
[F3]Exercise: $69.41Exp: 2032-02-23→ Common Stock (30,193 underlying) - 26,079
Stock Option
[F4]Exercise: $78.28Exp: 2033-02-28→ Common Stock (26,079 underlying) - 11,399
Stock Option
[F5]Exercise: $95.74Exp: 2034-02-27→ Common Stock (11,399 underlying) - 9,467
Stock Option
[F6]Exercise: $116.41Exp: 2035-02-25→ Common Stock (9,467 underlying)
Footnotes (6)
- [F1]Price reflected is the weighted average sale price for shares sold. The range of sales prices for the transactions reported was $141.81 - $141.87 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F2]The options became fully exercisable on February 23, 2024, the third anniversary of the grant date.
- [F3]The options became fully exercisable on February 23, 2025, the third anniversary of the grant date.
- [F4]One-third of the options became exercisable on February 28, 2024, an additional one-third of the options became exercisable on February 28, 2025 and the remaining one-third of the options will become exercisable on February 28, 2026, the third anniversary of the grant date.
- [F5]One-third of the options became exercisable on February 27, 2025, an additional one-third of the options will become exercisable on February 27, 2026 and the remaining one-third of the options will become exercisable on February 27, 2027, the third anniversary of the grant date.
- [F6]One-third of the options will become exercisable on February 25, 2026, an additional one-third of the options will become exercisable on February 25, 2027 and the remaining one-third of the options will become exercisable on February 25, 2028, the third anniversary of the grant date.
Signature
Anthony J. Salerno, Jr., Attorney-in-Fact|2026-02-13